DNMT1 and myelodysplastic syndrome: DNMT inhibitors (DNMTi) [24, 56], such as nucleoside analogs including 5‐azacytidine (5‐AZA), 5‐aza‐2′‐deoxycytidine (decitabine), and SGI‐110 (guadecitabine), have demonstrated clinical efficacy in hematologic malignancies, including myelodysplastic syndrome (MDS), AML, and chronic myelomonocytic leukemia [57, 58, 59].